Does SF3B1/TET2 Double Mutation Portend Better or Worse Prognosis Than Isolated SF3B1 or TET2 Mutation?

Abstract

Background: Mutations in splicing factor 3b 91 This article is freely accessible online.Correspondence to:

Roles of ten‑eleven translocation family proteins and their O‑linked β‑N‑acetylglucosaminylated forms in cancer development (Review)

“…1 ). These three versions of oxidized methylcytosines are all associated with DNA demethylation ( 16 , 17 ).…”

“…1). These three versions of oxidized methylcytosines are all associated with DNA demethylation (16,17). TET proteins have a common cysteine-rich dioxygenase region and C-terminal region which binds to ferrous iron and α-ketoglutarate and catalyzes an oxidation reaction which involves hydroxylation of 5mC to 5hmC and further to 5fC and 5caC (12).…”

Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features

“…SF3B1 mutations often co-occur with TET2 mutations [24]. Double mutant mice generated by the breeding of Sf3b1 +/K700E and Tet2 knock-out mice manifested a more severe anemia compared to mice with a sole alteration in Sf3b1 or Tet2 [12].…”

Co-mutation ofASXL1andSF3B1Predicts Poorer Overall Survival Than IsolatedASXL1orSF3B1Mutations

“…NGS and statistical analyses. As has been described in detail in in our previous studies (38,39), in-house targeted NGS was performed using Illumina MiSeq or NexSeq500 instruments (Illumina, San Diego, CA, USA). The following most frequently mutated genes in myeloid neoplasms were tested in our in-house, 54-gene panel by NGS: ABL proto-oncogene 1 (ABL1), ASXL1, ATRX chromatin remodeler (ATRX), BCL6 co-repressor (BCOR), BCL6 corepressorlike 1 (BCORL1), B-Raf proto-oncogene (BRAF), calreticulin (CALR), Cbl proto-oncogene (CBL), CBLB,CBLC, cyclin-dependent kinase inhibitor 2A (CDKN2A), CEBPA, colony-stimulating factor 3 receptor (CSF3R), Cut-like homeobox 1 (CUX1), DNMT3A, ETS variant transcription factor 6 (ETV6), enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), F-box and WD repeat domain-containing 7 (FBXW7), FLT3, GATA1, GATA2, GNAS complex locus (GNAS), HRas proto-oncogene (HRAS), IDH1, IDH2, IKAROS family zinc finger 1 (IKZF1), JAK2, JAK3, lysine demethylase 6A (KDM6A), KIT proto-oncogene (KIT), lysine methyltransferase 2A (KMT2A), KRAS proto-oncogene (KRAS), MPL proto-oncogene (MPL), MYD88 innate immune signal transduction adaptor (MYD88), notch receptor 1 (NOTCH1), NPM1, NRAS, platelet-derived growth factor receptor alpha (PDGFRA), PHD finger protein 6 (PHF6), phosphatase and tensin homolog (PTEN), protein tyrosine phosphatase non-receptor type 11 (PTPN11), RAD21 cohesin complex component (RAD21), RUNX1, SETBP1, SF3B1, structural maintenance of chromosomes 1A (SMC1A), structural maintenance of chromosomes 3 (SMC3), SRSF2, STAG2, TET2, Tumor protein p53 (TP53), U2AF1, WT1 transcription factor (WT1), and zinc finger CCCH-type, RNAbinding motif and serine/arginine-rich 2 (ZRSR2).…”